Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vose

Showing results (591-600 of 891) with videos related to

Pageof 90
Sort By:
British Journal of Haematology|July 10, 2013
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantationJulie M Vose, Thomas M Habermann, Myron S Czuczman, et al.
F1000Research|July 29, 2020
Toward a paradigm shift from deficit-based to proactive speech and language treatment: Randomized pilot trial of the Babble Boot Camp in infants with classic galactosemiaBeate Peter, Nancy Potter, Jennifer Davis, et al.
British Journal of Haematology|April 27, 2013
CD43 expression is associated with inferior survival in the non-germinal centre B-cell subgroup of diffuse large B-cell lymphomaZdravko Mitrovic, Javeed Iqbal, Kai Fu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1996
Phase I trial of recombinant fusion protein PIXY321 for mobilization of peripheral-blood cellsM R Bishop, J D Jackson, B O'Kane-Murphy, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|November 1, 2000
[Development of molecular targeting drugs for the treatment of cancer-therapeutic potential and issues to be addressed in global development]H Akaza, K Aiba, S Isonishi, et al.
Journal of Hematotherapy|April 1, 1995
Comparison of subcutaneous and intravenous administration of recombinant human granulocyte-macrophage colony-stimulating factor for peripheral blood stem cell mobilizationA Kessinger, M R Bishop, J R Anderson, et al.
Journal of Oncology Practice|October 25, 2019
Assessing an ASCO Decision Aid for Improving the Accuracy and Attribution of Serious Adverse Event Reporting From Investigators to SponsorsKathryn F Mileham, Caroline Schenkel, Meredith K Chuk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2005
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomasRichard I Fisher, Mark S Kaminski, Richard L Wahl, et al.
Journal of Surgical Oncology|July 12, 2011
Quantitative comparison of surgical margin histology following excision with traditional electrosurgery and a low-thermal-injury dissection deviceManuel E Ruidiaz, Maria J Cortes-Mateos, Sergio Sandoval, et al.
Journal of Neurotrauma|March 12, 2024
Cardiorespiratory Responses to Acute Intermittent Hypoxia in Humans With Chronic Spinal Cord InjuryJoseph F Welch, Alicia K Vose, Kate Cavka, et al.
Pageof 90

Showing results (591-600 of 891) with videos related to

Sort By:
Pageof 90
British Journal of Haematology|July 10, 2013
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantationJulie M Vose, Thomas M Habermann, Myron S Czuczman, et al.
F1000Research|July 29, 2020
Toward a paradigm shift from deficit-based to proactive speech and language treatment: Randomized pilot trial of the Babble Boot Camp in infants with classic galactosemiaBeate Peter, Nancy Potter, Jennifer Davis, et al.
British Journal of Haematology|April 27, 2013
CD43 expression is associated with inferior survival in the non-germinal centre B-cell subgroup of diffuse large B-cell lymphomaZdravko Mitrovic, Javeed Iqbal, Kai Fu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1996
Phase I trial of recombinant fusion protein PIXY321 for mobilization of peripheral-blood cellsM R Bishop, J D Jackson, B O'Kane-Murphy, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|November 1, 2000
[Development of molecular targeting drugs for the treatment of cancer-therapeutic potential and issues to be addressed in global development]H Akaza, K Aiba, S Isonishi, et al.
Journal of Hematotherapy|April 1, 1995
Comparison of subcutaneous and intravenous administration of recombinant human granulocyte-macrophage colony-stimulating factor for peripheral blood stem cell mobilizationA Kessinger, M R Bishop, J R Anderson, et al.
Journal of Oncology Practice|October 25, 2019
Assessing an ASCO Decision Aid for Improving the Accuracy and Attribution of Serious Adverse Event Reporting From Investigators to SponsorsKathryn F Mileham, Caroline Schenkel, Meredith K Chuk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2005
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomasRichard I Fisher, Mark S Kaminski, Richard L Wahl, et al.
Journal of Surgical Oncology|July 12, 2011
Quantitative comparison of surgical margin histology following excision with traditional electrosurgery and a low-thermal-injury dissection deviceManuel E Ruidiaz, Maria J Cortes-Mateos, Sergio Sandoval, et al.
Journal of Neurotrauma|March 12, 2024
Cardiorespiratory Responses to Acute Intermittent Hypoxia in Humans With Chronic Spinal Cord InjuryJoseph F Welch, Alicia K Vose, Kate Cavka, et al.
Pageof 90